Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.

Also called NCT01338870

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 301 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01338870
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Hungary, Mexico, Slovakia, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01338870. Randomized; double masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-04-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
25 mg PF-04991532
Intervention (Drug)
75 mg PF-04991532
Intervention (Drug)
150 mg PF-04991532
Intervention (Drug)
300 mg PF-04991532
Intervention (Drug)
Sitagliptin 100 mg
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01338870
Content hash
b0c2c5963d8f8f6b44dedcd75f003565d313a47ea0d715143d5c84c3b510d610